J Clin Endocrinol Metab . Before and at the end of treatment, hirsutism was quantitatively measured in each subject by determination, by computer-assisted light microscopy, of the largest diameter of 5 hairs plucked from the linea alba. 2018 Mar;31(2):e12588.
Reference: Barrionuevo P, Nabhan M, Altayar O, et al. 2019 Oct;24(7):973-983. doi: 10.1007/s00775-019-01692-z. User Reviews for Finasteride. Further research should investigate the potential for synergic effects of combined therapies with drugs acting at different levels in androgen secretion and/or action.We thank Ms. Alessandra Rossi and Ms. M. Grazia Zanotti for their invaluable assistance. In addition, safety parameters were assessed before treatment and at 2-month intervals during the study. This device included an IBM enhanced AT computer, two full-color display monitors, a graphics and system control/menu selection monitor, and a digital image display for displaying real-time digital images. These consisted of waxing (n = 20), waxing and plucking (n = 2), waxing and shaving (n = 1), or depilatory cream (n = 1), with variable frequency (2–30 days). An objective evaluation of hirsutism in each patient was obtained by averaging the largest diameters of five hairs plucked, using regular facial tweezers, from a 2 × 2-cm area in the linea alba. Lumachi F, Rondinone R. Use of Cyproterone Acetate, Finasteride and Spironolactone to Treat Idiopathic Hirsutism. Background: Physicians are beginning to use finasteride as treatment for hair loss, hirsutism, and various other dermatologic conditions in women. Search for other works by this author on: With this method, both intra- and intersubject mean coefficients of variation were less than 2%.A semiquantitative, clinical evaluation of hirsutism was also performed in these subjects by a modification of the F-G method (The patients’ subjective opinion of the clinical outcome of therapy (excellent, good, fair, or poor) was also obtained. The 15-epilipoxin-A4 pathway (ATL) with prophylactic aspirin in preventing preeclampsia: a longitudinal-cohort study eCollection 2020.Drug Des Devel Ther. Search for other works by this author on: To be considered clinically significant, changes in safety parameters had to either exceed the normal limits or double the baseline values.Hair growth assessment included both an objective method and a hirsutism score, graded by a modified F-G method.
Standard hormonal profiles, before and after treatment, in the four treatment groupsTABLE 3. Hip structural analysis reveals impaired hip geometry in girls with type 1 diabetes
Endocrinol. Furthermore, hair growth changes were measured not only by the subjective F-G scoring, commonly used in clinical practice as a semiquantitative measure of degree of hirsutism, but also by an objective method, measurement of hair shaft diameters. doi: 10.1111/dth.12647. eCollection 2020 May.Rossi A, Magri F, D'Arino A, Pigliacelli F, Muscianese M, Leoncini P, Caro G, Federico A, Fortuna MC, Carlesimo M.Dermatol Pract Concept. Leuprolide and estrogen vs oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.Hirsutism and the effectiveness of spironolactone in its management.Pharmacology and potential use of cyproterone acetate.Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues.Inhibition of rat testicular 17α-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) Effects of flutamide and aminoglutethimide on plasma 5α-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.Treatment of hirsutism with the pure antiandrogen flutamide.The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism.Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior.Fatal and nonfatal hepatotoxicity associated with flutamide.Genetic and pharmacological evidence for more than one human steroid 5α-reductase.Increased 5α reductase activity in idiopathic hirsutism.Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism.A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up.Gonadotropin-releasing hormone (GnRH) agonist and estrogen/progestin replacement for the treatment of hirsutism: evaluating the results [Editorial].How robust is the methodology for trials of therapy in hirsute women?Comparison of sequential cyproterone acetate/estrogen Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome.Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.Optical microscope system for standardized cell measurements and analyses.Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial.Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy.Comparison of diane 35 and diane 35 plus spironolactone in the treatment of hirsutism.A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism.The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.Hepatotoxicity complicating flutamide treatment of hirsutism [Letter].The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
On the other hand, no change was reported by women receiving placebo.Patients’ self-evaluations of clinical outcome at the end of the study were also consistent with changes in hair diameter and hirsutism score (Patients’ self-evaluation of clinical outcome of the therapyPatients’ self-evaluation of clinical outcome of the therapyTABLE 3.
The initial research was very encouraging.
This observation is not surprising, as subjective perception of hair growth excess depends not only on hair diameter, but also on the length and density of terminal hairs.The present controlled trial demonstrates that spironolactone, flutamide, and finasteride are effective in the treatment of hirsutism, supporting conclusions of previous, almost all uncontrolled, studies (Spironolactone has been given to hirsute women in previous studies in doses ranging from 50–400 mg/day (We cannot exclude that by using different doses of drugs or by extending the duration of treatments it might be possible to identify some differences in clinical efficacy among these drugs. Unable to load your delegates due to an error